argenx SE (NASDAQ:ARGX) Receives $596.78 Average Price Target from Analysts

argenx SE (NASDAQ:ARGX - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-three analysts that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $596.78.

Several research firms have issued reports on ARGX. Deutsche Bank Aktiengesellschaft downgraded argenx from a "buy" rating to a "hold" rating in a report on Friday, October 4th. Truist Financial upped their price target on shares of argenx from $540.00 to $660.00 and gave the company a "buy" rating in a research report on Thursday. Barclays upgraded shares of argenx from an "equal weight" rating to an "overweight" rating in a research report on Tuesday, August 6th. William Blair upgraded argenx from a "market perform" rating to an "outperform" rating in a report on Friday. Finally, Guggenheim lifted their price target on argenx from $585.00 to $665.00 and gave the company a "buy" rating in a report on Friday.

Institutional Trading of argenx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Profund Advisors LLC increased its position in shares of argenx by 3.0% during the second quarter. Profund Advisors LLC now owns 973 shares of the company's stock valued at $418,000 after purchasing an additional 28 shares during the period. Wealth Alliance lifted its holdings in shares of argenx by 4.8% during the 2nd quarter. Wealth Alliance now owns 628 shares of the company's stock worth $270,000 after acquiring an additional 29 shares during the period. GAMMA Investing LLC boosted its position in shares of argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company's stock valued at $51,000 after acquiring an additional 40 shares in the last quarter. Toronto Dominion Bank increased its stake in argenx by 16.5% in the first quarter. Toronto Dominion Bank now owns 303 shares of the company's stock valued at $119,000 after acquiring an additional 43 shares during the period. Finally, Sequoia Financial Advisors LLC increased its stake in argenx by 3.1% in the second quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company's stock valued at $737,000 after acquiring an additional 52 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Performance

Shares of NASDAQ:ARGX traded up $9.28 during trading hours on Friday, hitting $595.58. 468,633 shares of the company's stock traded hands, compared to its average volume of 226,013. argenx has a 52 week low of $327.73 and a 52 week high of $610.73. The company's fifty day simple moving average is $539.46 and its two-hundred day simple moving average is $466.48.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 0.96% and a negative net margin of 2.11%. The business had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. During the same period in the previous year, the firm posted ($1.25) EPS. Analysts forecast that argenx will post -0.36 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.